AZD9898

Research use only, not for human use.

AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 has the potential to treat asthma. AZD9898 mitigates the GABA binding and hepatic toxicity signal.

AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 has the potential to treat asthma. AZD9898 mitigates the GABA binding and hepatic toxicity signal.(In Vivo):AZD9898 (10 and 100 mg/kg; oral) is well tolerated and shows no safety concerns.

——

AZD9898 with the single dose of 100 mg/kg is well tolerated and no safety concerns are raised. Animal Model:Rat 6M/group.Dosage:10 and 100 mg/kg (for Toxicology Study).Administration:Sing oral dose.Result:Showed no signs of testicular toxicity, and only adaptive changes in the liver due to cytochrome P450 induction which were not judged adverse, providing a 200 fold margin between the no adverse effect level and the predicted human exposure at the predicted therapeutic dose.

——

Others

Other Targets

Antifungal

——

——

2042347-69-1

457.83

C20H19ClF3N3O4

>98% (HPLC)

In Vitro:?DMSO : ≥ 250 mg/mL (546.05 mM)

COc1nc(cnc1C(=O)[C@H]1C[C@@H]1C(O)=O)N(CC(C)(C)F)c1cc(Cl)c(F)cc1F

——

(-20℃)

With Ice Pack

≥ 2 years